Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclerion Therapeutics Inc (NQ: CYCN )

2.870 +0.100 (+3.61%)
Streaming Delayed Price Updated: 9:30 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 156
Open 2.870
Bid (Size) 2.900 (1)
Ask (Size) 3.200 (1)
Prev. Close 2.770
Today's Range 2.870 - 2.870
52wk Range 1.750 - 6.750
Shares Outstanding 43,524,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023
Cyclerion Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga

Performance

YTD
-18.00%
-18.00%
1 Month
-5.28%
-5.28%
3 Month
-18.00%
-18.00%
6 Month
-5.59%
-5.59%
1 Year
-48.53%
-48.53%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Cyclerion Appoints Regina Graul, Ph.D., as President
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cyclerion Announces Reverse Stock Split
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors
Via Benzinga
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.